Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

X4 Pharmaceuticals (XFOR) Shares Outstanding (Weighted Average) (2018 - 2025)

Historic Shares Outstanding (Weighted Average) for X4 Pharmaceuticals (XFOR) over the last 8 years, with Q3 2025 value amounting to $43.3 million.

  • X4 Pharmaceuticals' Shares Outstanding (Weighted Average) rose 54629.55% to $43.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.3 million, marking a year-over-year increase of 54629.55%. This contributed to the annual value of $201.1 million for FY2024, which is 1307.54% up from last year.
  • According to the latest figures from Q3 2025, X4 Pharmaceuticals' Shares Outstanding (Weighted Average) is $43.3 million, which was up 54629.55% from $7.4 million recorded in Q2 2025.
  • X4 Pharmaceuticals' Shares Outstanding (Weighted Average)'s 5-year high stood at $201.1 million during Q4 2024, with a 5-year trough of $6.7 million in Q1 2024.
  • Over the past 5 years, X4 Pharmaceuticals' median Shares Outstanding (Weighted Average) value was $33.7 million (recorded in 2022), while the average stood at $67.6 million.
  • Per our database at Business Quant, X4 Pharmaceuticals' Shares Outstanding (Weighted Average) tumbled by 9660.11% in 2024 and then skyrocketed by 54629.55% in 2025.
  • Quarter analysis of 5 years shows X4 Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $25.7 million in 2021, then surged by 146.71% to $63.5 million in 2022, then skyrocketed by 179.91% to $177.8 million in 2023, then grew by 13.08% to $201.1 million in 2024, then plummeted by 78.48% to $43.3 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $43.3 million for Q3 2025, versus $7.4 million for Q2 2025 and $6.8 million for Q1 2025.